Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 23, Issue 2, 2013, Pages 256-263

  Chen, Lifeng ^a   Liang, Lizhi ^b   Yan, Xiaojian ^a   Liu, Naihua ^c   Gong, Lihua ^a   Pan, Shishi ^a   Lin, Feng ^a   Zhang, Qian ^a   Zhao, Hongqin ^a   Zheng, Feiyun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Ovarian neoplasms; RNA interference; Short hairpin RNA; Survivin

Indexed keywords

CISPLATIN; MESSENGER RNA; MOLECULAR MARKER; PACLITAXEL; SHORT HAIRPIN RNA; SURVIVIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CHEMOSENSITIVITY; CHINESE; CONTROLLED STUDY; CYTOPLASM; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; G2 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SURVIVAL RATE; SURVIVAL TIME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; PROGNOSIS; RETROSPECTIVE STUDIES; RNA, SMALL INTERFERING; YOUNG ADULT;

EID: 84876256528     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31827ad2b8     Document Type: Article

References (35)

1. Tingulstad S, Skjeldestad FE, Halvorsen TB, et al. Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol. 2003;101:885-891.
2. Yamashita S, Masuda Y, Kurizaki T, et al. Survivin expression predicts early recurrence in early-stage breast cancer. Anticancer Res. 2007;27:2803-2808.
3. Gordon GJ, Mani M, Mukhopadhyay L, et al. Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma. J Pathol. 2007;211: 439-446.
4. Li F, Ling X. Survivin study: An update of "what is the next wave"? J Cell Physiol. 2006;208:476-486.
5. Yamamoto H, Ngan CY, Monden M. Cancer cells survive with survivin. Cancer Sci. 2008;99:1709-1714.
6. Zhang M, Coen JJ, Suzuki Y, et al. Survivin is a potential mediator of prostate cancer metastasis. Int J Radiat Oncol Biol Physics. 2010;78:1095-1103.
7. Altieri DC. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol. 2006;18:609-615.
8. Wheatley SP, McNeish IA. Survivin: A protein with dual roles in mitosis and apoptosis. Int Rev Cytol. 2005;247:35-88.
9. Ferrandina G, Legge F, Martinelli E, et al. Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br J Cancer. 2005;92:271-277.
10. Sui L, Dong Y, Ohno M, et al. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int J Oncol. 2002;21:315-320.
11. Takai N, Miyazaki T, Nishida M, et al. Expression of survivin is associated with malignant potential in epithelial ovarian carcinoma. Int J Mol Med. 2002;10:211-216.
12. Qian X, Xi X, Li L. Nuclear survivin is associated with malignant potential in epithelial ovarian carcinoma. Appl Immunohistochem Mol Morphol. 2011;19:126-132.
13. Montazeri Aliabadi H, Landry B, Mahdipoor P, et al. Induction of apoptosis by survivin silencing through siRNA delivery in a human breast cancer cell line. Mol Pharm. 2011;8:1821-1830.
14. Zaffaroni N, Pennati M, Daidone MG. Survivin as a target for new anticancer interventions. J Cell Mol Med. 2005;9:360-372.
15. Chen YC, Song C, Luo CQ. Short hairpin RNAs induced RNA interference in human cells. Chinese J Cancer. 2003;22: 566-570.
16. Zaffaroni N, Pennati M, Colella G, et al. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci. 2002;59:1406-1412.
17. Yoshida H, Ishiko O, Sumi T, et al. Survivin, bcl-2 and matrix metalloproteinase-2 enhance progression of clear cellY and serous-type ovarian carcinomas. Int J Oncol. 2001;19:537-542.
18. Wang Z, Xie Y, Wang H. Changes in survivin messenger RNA level during chemotherapy treatment in ovarian cancer cells. Cancer Biol Ther. 2005;4:716-719.
19. Athanassiadou P, Grapsa D, Athanassiades P, et al. The prognostic significance of COX-2 and survivin expression in ovarian cancer. Pathol Res Pract. 2008;204:241-249.
20. No JH, Jeon YT, Kim YB, et al. Quantitative detection of serum survivin and its relationship with prognostic factors in ovarian cancer. Gynecol Obstet Invest. 2011;71:136-140.
21. Ma X, Wang S, Zhou J, et al. Induction of apoptosis in human ovarian epithelial cancer cells by antisurvivin oligonucleotides. Oncol Rep. 2005;14:275-279.
22. Xing J, Jia CR, Wang Y, et al. Effect of shRNA targeting survivin on ovarian cancer. J Cancer Res Clin Oncol. 2012;138:1221-1229.
23. Hoskins G, Neville RG, McCowan C, et al. Scottish Asthma Management Initiative. Health Bull. 2000;58:478-488.
24. Salvesen GS, Duckett CS. IAP proteins: Blocking the road to death's door. Nat Rev Mol Cell Biol. 2002;3:401-410.
25. Takai N, Miyazaki T, Nishida M, et al. Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma. Cancer Lett. 2002;184:105-116.
26. Nakahara T, Takeuchi M, Kinoyama I, et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 2007;67:8014-8021.
27. Song H, Xin XY, Xiao F, et al. Survivin gene RNA interference inhibits proliferation, induces apoptosis, and enhances radiosensitivity in HeLa cells. Eur J Obstet Gynecol Reprod Biol. 2008;136:83-89.
28. Deng KX, Zhong L, Jiang MX, et al. RNA interference silencing expression of survivin gene and reversing drug resistance of ovarian cancer cell line SKOV3/ADM [in Chinese]. Zhonghua Fu Chan Ke Za Zhi. 2005;40:836-839.
29. Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 2000; 18:3084-3092.
30. Ozols RF. Paclitaxel (taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer. Semin Oncol. 2000;27:3-7.
31. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents. 2002;2:1-17.
32. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194-3200.
33. von Haefen C, Wieder T, Essmann F, et al. Paclitaxel-induced apoptosis in BJABcells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loop. Oncogene. 2003;22:2236-2247.
34. Song Z, Yao X, Wu M. Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem. 2003;278:23130-23140.
35. Zhu G, Myint M, Ang WH, et al. Monofunctional platinum-DNA adducts are strong inhibitors of transcription and substrates for nucleotide excision repair in live mammalian cells. Cancer Res. 2012;72:790-800.